Abivax stock crashed Monday after several patients developed cancer following a study of its ulcerative colitis treatment.

Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.

The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment.

Treatment failure occurs when an ulcerative colitis medication isn’t helping symptoms. Most important, know that it’s not your fault. Learn what to do next.

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

The Crohn's & Colitis Foundation's largest fundraising event is "Take Steps", where all proceeds raised go towards medical ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Ulcerative colitis is a condition that affects your colon and rectum. Its symptoms vary based on how severe it is. They can range from mild cases with a few stomach cramps and constipation, to more ...